CELLECTIS (ALCLS)

CELLECTIS
Sell: €1.38|Buy: €1.42|Change: 0.01 (0.43%)

Open 

€1.42


Previous close 

€1.39


Trade high 

€1.42


Volume 

62,098


Year high 

€3.025


Year low 

€1.012


Dividend yield 


Market capitalisation 

€140.00 mn


P/E ratio 


ISIN 

FR0010425595


Share price

Performance 30/04/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
CELLECTIS+ 0.43
More...

Company profile

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.